Last reviewed · How we verify
Beclomethasone dipropionate/Salbutamol combination
Beclomethasone dipropionate/Salbutamol combination is a Inhaled corticosteroid/short-acting beta-2 agonist (ICS/SABA) combination Small molecule drug developed by Chiesi Farmaceutici S.p.A.. It is currently in Phase 3 development for Asthma maintenance and reliever therapy, Chronic obstructive pulmonary disease (COPD).
This combination inhaler delivers a corticosteroid to reduce airway inflammation and a short-acting beta-2 agonist to rapidly relax bronchial smooth muscle.
This combination inhaler delivers a corticosteroid to reduce airway inflammation and a short-acting beta-2 agonist to rapidly relax bronchial smooth muscle. Used for Asthma maintenance and reliever therapy, Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | Beclomethasone dipropionate/Salbutamol combination |
|---|---|
| Sponsor | Chiesi Farmaceutici S.p.A. |
| Drug class | Inhaled corticosteroid/short-acting beta-2 agonist (ICS/SABA) combination |
| Target | Glucocorticoid receptor (beclomethasone); beta-2 adrenergic receptor (salbutamol) |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | Phase 3 |
Mechanism of action
Beclomethasone dipropionate is a inhaled corticosteroid that suppresses inflammatory responses in the airways by binding glucocorticoid receptors, reducing mucus production and airway edema. Salbutamol (albuterol) is a short-acting beta-2 adrenergic agonist that activates beta-2 receptors on bronchial smooth muscle, causing rapid bronchodilation. Together, they provide both rapid symptom relief and sustained anti-inflammatory control in asthma and COPD.
Approved indications
- Asthma maintenance and reliever therapy
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Tremor
- Headache
- Palpitations
- Oral candidiasis
- Hoarseness
- Nervousness/anxiety
Key clinical trials
- Anti-Inflammatory Reliever South Africa (PHASE3)
- Individualizing Treatment for Asthma in Primary Care (Full Study) (PHASE4)
- Individualizing Treatment for Asthma in Primary Care (PHASE4)
- CIVETTA: Correlating Inflammatory Values of FEno, SympToms, SpuTum and Lung Function in Asthma (PHASE2)
- Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease (PHASE4)
- Study of the Effect of Mometasone Furoate/Formoterol (MF/F), Montelukast and Beclomethasone Dipropionate (BDP) on Plasma Cortisol Levels of Children 5-11 Years Old With Persistent Asthma (P05574) (PHASE2)
- Non-invasive Measures of Distal Lung Disease in Asthmatics (PHASE4)
- Personalized Treatment Algorithms for Difficult-to-treat Asthma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Beclomethasone dipropionate/Salbutamol combination CI brief — competitive landscape report
- Beclomethasone dipropionate/Salbutamol combination updates RSS · CI watch RSS
- Chiesi Farmaceutici S.p.A. portfolio CI
Frequently asked questions about Beclomethasone dipropionate/Salbutamol combination
What is Beclomethasone dipropionate/Salbutamol combination?
How does Beclomethasone dipropionate/Salbutamol combination work?
What is Beclomethasone dipropionate/Salbutamol combination used for?
Who makes Beclomethasone dipropionate/Salbutamol combination?
What drug class is Beclomethasone dipropionate/Salbutamol combination in?
What development phase is Beclomethasone dipropionate/Salbutamol combination in?
What are the side effects of Beclomethasone dipropionate/Salbutamol combination?
What does Beclomethasone dipropionate/Salbutamol combination target?
Related
- Drug class: All Inhaled corticosteroid/short-acting beta-2 agonist (ICS/SABA) combination drugs
- Target: All drugs targeting Glucocorticoid receptor (beclomethasone); beta-2 adrenergic receptor (salbutamol)
- Manufacturer: Chiesi Farmaceutici S.p.A. — full pipeline
- Therapeutic area: All drugs in Respiratory/Pulmonology
- Indication: Drugs for Asthma maintenance and reliever therapy
- Indication: Drugs for Chronic obstructive pulmonary disease (COPD)
- Compare: Beclomethasone dipropionate/Salbutamol combination vs similar drugs
- Pricing: Beclomethasone dipropionate/Salbutamol combination cost, discount & access